Life-threatening drug interactions: what the physician needs to know

Internal Medicine Journal
Richard O DayAndrew J McLachlan

Abstract

Adverse drug-drug interactions are a significant cause of adverse events and outcomes. Their incidence is rising, with more patients taking more drugs, and newer, more precise but often more hazardous drugs becoming available. Despite considerable information, including computerised alerts about potential adverse drug-drug interactions, prescribers increasingly override alerts, possibly symptomatic of the immense problem of evaluating the risk of an interaction in a particular patient. Many reports emanate from small studies often of normal and young volunteers, entirely different from the real world where, more often, older patients with multiple health conditions are receiving many more than the two drugs identified in the drug interaction report. Focusing on those drug-drug interactions that are clinically relevant is necessary, and increasingly, tools and reliable sources of this information are easily accessible.

References

Aug 14, 1975·The New England Journal of Medicine·G LevyL K Garrettson
Aug 1, 1978·Clinical Pharmacology and Therapeutics·S WaldorffE Steiness
Mar 1, 1991·British Journal of Clinical Pharmacology·N R Campbell, B B Hasinoff
Sep 7, 1995·The New England Journal of Medicine·A KeoghA Kaan
Mar 6, 1998·British Journal of Rheumatology·A Steuer, J M Gumpel
Jul 1, 1998·Clinical Pharmacokinetics·R E BullinghamB R Kamm
Feb 16, 1999·Archives of Internal Medicine·H Ben-AmiY Edoute
Jul 20, 1999·The Journal of Clinical Investigation·B GreinerH K Kroemer
Apr 20, 2000·The Medical Journal of Australia·M C Thomas
Apr 16, 2002·Epilepsia·Philip N PatsalosClementina M van Rijn
Jun 14, 2002·Pharmacy World & Science : PWS·H J M Beijer, C J de Blaey
Mar 6, 2003·Journal of Clinical Pharmacology·Mark J SheltonGene D Morse
Apr 4, 2003·JAMA : the Journal of the American Medical Association·David N JuurlinkDonald A Redelmeier
Apr 12, 2003·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Weeranuj YamreudeewongDennis L Lower
Apr 17, 2004·Journal of the American Geriatrics Society·David N JuurlinkDonald A Redelmeier
Apr 20, 2004·British Journal of Clinical Pharmacology·Xuemin JiangAndrew J McLachlan
Jun 8, 2004·Current Medicinal Chemistry·P D CoxeterB D Roufogalis
Apr 5, 2005·The Medical Journal of Australia·Richard O DayJ Paul Seale
Dec 21, 2006·Clinical Pharmacology and Therapeutics·Pertti J NeuvonenJanne T Backman
Dec 26, 2006·Pharmacy World & Science : PWS·Matthijs L BeckerBruno H Ch Stricker
Sep 19, 2007·The Medical Journal of Australia·Geoffrey K IsbisterIan M Whyte
Jan 4, 2008·European Journal of Clinical Pharmacology·Uwe Fuhr
Jul 3, 2008·The Annals of Pharmacotherapy·Chuenjid KongkaewDarren M Ashcroft
Oct 7, 2008·Current Problems in Cardiology·Ilan GoldenbergArthur J Moss
May 25, 2010·Journal of Gastroenterology and Hepatology·Richard B GearryMiles P Sparrow
Jul 27, 2010·British Journal of Clinical Pharmacology·Elizabeth E RougheadAndrew L Gilbert
Dec 24, 2010·Journal of Gastroenterology and Hepatology·Sharon J GardinerMurray L Barclay
Jan 13, 2011·British Journal of Clinical Pharmacology·Thomas M PolasekMatthew P Doogue
Nov 1, 2011·Pharmacoepidemiology and Drug Safety·Agnes I VitryRobyn A McDermott
Jan 20, 2012·The Medical Journal of Australia·Tessa K MorganJoanne Barnes
Feb 4, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Bella PajaresEmilio Alba
Aug 8, 2012·Expert Opinion on Drug Safety·Stefano Bellosta, Alberto Corsini
Oct 2, 2012·CNS Drugs·Yumiko AkamineTsukasa Uno
Jan 9, 2013·Psychosomatics·Scott R BeachJeff C Huffman
Feb 21, 2014·BMJ : British Medical Journal·Nicholas A BuckleyGeoffrey K Isbister
Mar 13, 2014·Pharmacoepidemiology and Drug Safety·Supinya DechanontChuenjid Kongkaew
Jul 6, 2014·The Lancet Oncology·Roelof W F van LeeuwenFrank G A Jansman
Jul 19, 2014·BMJ : British Medical Journal·Chintan S DesaiRoger S Blumenthal
Sep 6, 2014·European Journal of Clinical Pharmacology·Johan HolmBuster Mannheimer
Jan 20, 2015·Alcoholism, Clinical and Experimental Research·Rosalind A BreslowAaron White

❮ Previous
Next ❯

Citations

Aug 11, 2018·Expert Opinion on Drug Metabolism & Toxicology·Joshua SchreckerDavid M Schwope
Jan 10, 2018·Internal Medicine Journal·Jeff Szer
Nov 7, 2019·São Paulo Medical Journal = Revista Paulista De Medicina·Bianca Menezes DiasAdriano Max Moreira Reis
Jul 12, 2019·Medical Mycology·Ruth Van DaeleRoger Brüggemann
Apr 9, 2019·Therapeutic Advances in Psychopharmacology·Emma TayRichard O Day
Jan 24, 2020·BMJ Case Reports·James David van OppenAamir Tarique
Jun 20, 2020·Drug and Therapeutics Bulletin·James David van OppenAamir Tarique
Nov 28, 2020·Journal of Analytical Toxicology·Sarah M R Wille, Simon Elliott
May 7, 2020·Asian Journal of Pharmaceutical Sciences·Jiro OguraNariyasu Mano
Feb 6, 2021·Journal of the American Medical Informatics Association : JAMIA·Matthew T PatrickLam C Tsoi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinics in Podiatric Medicine and Surgery
T M Bianco
American Journal of Hypertension
Barry L CarterElizabeth Chrischilles
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
D Young
© 2022 Meta ULC. All rights reserved